

Hong Kong Exchanges and Clearing Limited and The Stock of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited

和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that X4 Pharmaceuticals, Inc., a partner of Abbisko Therapeutics Co., Ltd. (a subsidiary of the Company), has completed enrollment in the ongoing pivotal Phase 3 clinical trial of its lead candidate, mavorixafor, in the treatment of patients with genetically confirmed WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, a primary immunodeficiency caused by gain-of-function mutations in the CXCR4 gene.

This is a voluntary announcement made by the Company. The Group cannot guarantee that mavorixafor (ABSK081) will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, November 5, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping, Dr. Chen Zhui and Mr. Yeh Richard as executive directors; Dr. Xia Gavin Guoyao and Ms. Tang Yanmin as non-executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.

Abbisko’s Partner X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome

3 November, 2021, Shanghai – Abbisko Therapeutics Co., Ltd. (“**Abbisko**” hereafter) today announces that its partner X4 Pharmaceuticals, Inc. has completed enrollment in the ongoing pivotal Phase 3 clinical trial of its lead candidate, mavorixafor, in the treatment of patients with genetically confirmed WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, a primary immunodeficiency caused by gain-of-function mutations in the CXCR4 gene. Thirty-one adult and pediatric patients have enrolled in the 4WHIM trial, which compares a once-daily, oral dose of mavorixafor to placebo across primary and secondary endpoints that include clinically relevant counts of neutrophils and lymphocytes, the frequency and severity of both infections and warts, as well as certain quality of life measurements. The trial was originally designed to enroll 18-28 patients.

This was major milestone achievement for the thousands of WHIM patients with no disease-modifying treatment options. Top-line data from the 4WHIM trial is expected in the fourth quarter of 2022, and a regulatory filing likely will follow in the first quarter of 2023. In addition, we look forward to the availability of new long-term data from the ongoing Phase 2 open-label extension trial in WHIM as well as new research and clinical data later this year that may support broader market opportunities for mavorixafor across multiple indications.

Mavorixafor (ABSK081) is a first-in-class oral CXCR4 antagonist. Abbisko has obtained the exclusive rights in Greater China to develop and commercialize mavorixafor for oncology and WHIM indications. Abbisko will lead the clinical and commercial development of mavorixafor and has initiated the first of several planned clinical trials of mavorixafor in combination with other immuno-oncology or other therapeutic agents.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK) is an oncology focused biopharmaceutical company founded in Zhangjiang, Shanghai, dedicated to discovering and developing innovative medicines for unmet medical needs in China and around the world. The Company was formed by a group of seasoned drug researchers with rich R&D and management expertise in both top multinational pharmaceutical companies and Chinese industrial leaders. It is dedicated to first-in-class or best-in-class immuno-oncology and precision oncology therapies against novel and high potential molecular targets for unmet medical needs by adhering to global standards. Abbisko Therapeutics has built up an extensive internal discovery pipeline of 14 drug assets focused on precision oncology and immuno-oncology, including six clinical stage assets and eight pre-clinical stage assets. As of the date of this press release, we had received ten IND approvals in four countries and regions worldwide. Please visit www.abbisko.com.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.